These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31403862)

  • 1. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers.
    Lheureux S; Mirza M; Coleman R
    J Clin Oncol; 2019 Sep; 37(27):2449-2459. PubMed ID: 31403862
    [No Abstract]   [Full Text] [Related]  

  • 2. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond PARP-POLθ as an anticancer target.
    Higgins GS; Boulton SJ
    Science; 2018 Mar; 359(6381):1217-1218. PubMed ID: 29590065
    [No Abstract]   [Full Text] [Related]  

  • 5. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging DNA repair deficiency in gynecologic oncology.
    Walsh CS; Hodeib M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.
    Rajawat J; Shukla N; Mishra DP
    Front Biosci (Schol Ed); 2017 Jun; 9(3):343-356. PubMed ID: 28410123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
    Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors.
    Gaymes TJ; Shall S; Farzaneh F; Mufti GJ
    Haematologica; 2008 Dec; 93(12):1886-9. PubMed ID: 18838476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
    López-Camarillo C; Rincón DG; Ruiz-García E; Astudillo-de la Vega H; Marchat LA
    Curr Protein Pept Sci; 2019; 20(4):316-323. PubMed ID: 30215333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Exploiting DNA repair vulnerabilities with PARP inhibitors to stimulate anti-tumor immunity].
    Chabanon RM; Postel-Vinay S
    Med Sci (Paris); 2019 Oct; 35(10):728-731. PubMed ID: 31625890
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
    Wang Q; Peng H; Qi X; Wu M; Zhao X
    Signal Transduct Target Ther; 2020 Jul; 5(1):137. PubMed ID: 32728057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
    Tang YH; Lin CY; Lai CH
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
    Crafton SM; Bixel K; Hays JL
    Gynecol Oncol; 2016 Sep; 142(3):588-96. PubMed ID: 27168003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
    Nie Q; Omerza G; Chandok H; Prego M; Hsiao MC; Meyers B; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rowe S; Rueter J; Reddi HV
    Cancer Genet; 2020 Apr; 242():25-34. PubMed ID: 31992506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic gynecologic malignancies: advances in treatment and management.
    Chan JK; Chow S; Bhowmik S; Mann A; Kapp DS; Coleman RL
    Clin Exp Metastasis; 2018 Aug; 35(5-6):521-533. PubMed ID: 29931499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.